The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 HKD | +2.74% | -2.48% | +4.70% |
Apr. 30 | Hansoh Pharmaceutical’s 2023 Profit Up 27% | MT |
Apr. 29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.70% | 12.16B | |
+40.73% | 739B | |
+31.77% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.79% | 240B | |
+9.52% | 210B | |
-4.95% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer